ReviewFrontiers in public health2025
A review of pharmaceutical and personal care products and atopic dermatitis based on epidemiological and basic research findings.
Review in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmaceutical and personal care products (PPCPs) are emerging pollutants that have been found to be related to allergic diseases. Currently, a large amount of research focused on the association between PPCPs and atopic dermatitis (AD), but there has been no evaluation of existing evidence on this topic. Here, we reviewed epidemiological and toxicological studies from 2014 to 2024, with a focus on common PPCPs such as antibiotics, phthalates, p-hydroxybenzoic acid, etc. We found that most PPCPs are positively correlated with the onset of AD, with particular attention paid to exposure during pregnancy and infancy. This reminds AD patients to be cautious when taking medication and choosing nursing products. Animal studies have shown that the pathogenesis of PPCPs may be mediated by dysbiosis, immune imbalance and oxidative stress. Despite inconsistent results in existing research, PPCPs are confirmed to be unfavorable drivers of AD occurrence and progression. Clarifying their potential link with AD is critical for informing subsequent policy and regulatory decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.